Literature DB >> 20687794

How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection.

Cristina Scielzo1, Elisa Ten Hacken, Maria T S Bertilaccio, Marta Muzio, Carlo Calissano, Paolo Ghia, Federico Caligaris-Cappio.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation in primary and secondary lymphoid tissues of CD5+ B cells that have the same B cell receptor (BCR) rearrangement. Genetic alterations and different stimuli originating from the microenvironment cooperate in the selection and expansion of the malignant clone. Molecular and functional analyses suggest that stimulation through the BCR affects the destiny of leukemic cells in terms of life or death. Microenvironmental signals are crucial for this process, inducing proliferation and leading to the survival and accumulation of leukemic cells within lymphoid organs. Nevertheless, a number of major biological issues still remain to be solved, including the relationships between cell proliferation and cell accumulation within lymphoid organs as well as the mechanisms that regulate CLL cell migration and recirculation between peripheral blood and lymphoid tissues. We focused on the role played by the cytoskeleton, given its relevance in controlling cellular shape, mobility, and homing. We hypothesize that hematopoietic cell-specific Lyn substrate 1 (HS1), a putative prognostic marker in CLL that interacts with distinct cytoskeleton adapters in leukemic B-lymphocytes, could regulate the CLL cell cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687794     DOI: 10.3109/10428194.2010.505061

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.

Authors:  Lingzhi Zhang; Fiona Murray; Laura Z Rassenti; Minya Pu; Colleen Kelly; Joan R Kanter; Andrew Greaves; Karen Messer; Thomas J Kipps; Paul A Insel
Journal:  Int J Cancer       Date:  2011-02-11       Impact factor: 7.396

2.  Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.

Authors:  Xiao-Jie Yan; Igor Dozmorov; Wentian Li; Sophia Yancopoulos; Cristina Sison; Michael Centola; Preetesh Jain; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry
Journal:  Blood       Date:  2011-09-12       Impact factor: 22.113

3.  Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.

Authors:  Jolanta D Żołnierczyk; Oxana Komina; Jerzy Z Błoński; Arleta Borowiak; Barbara Cebula-Obrzut; Piotr Smolewski; Paweł Robak; Zofia M Kiliańska; Józefa Węsierska-Gądek
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

4.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

Review 5.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.